Charles River Laboratories International, Inc. (NYSE:CRL) Stock Rated “Moderate Buy” by Wall Street Brokerages

Charles River Laboratories International, Inc. (NYSE:CRL) has been given an average recommendation of “Moderate Buy” by the seventeen research firms that are currently covering the company, MarketBeat reports. One investment analyst has rated the stock with a sell recommendation, two have assigned a hold recommendation, twelve have given a buy recommendation and two have assigned a strong buy recommendation to the company. The average 1-year price target among brokers that have issued ratings on the stock in the last year is $302.33.

Several equities analysts recently weighed in on the company. Evercore set a $330.00 target price on Charles River Laboratories International in a research report on Friday, September 25th. TD Cowen lifted their price target on Charles River Laboratories International from $300.00 to $325.00 and gave the company a “buy” rating in a report on Friday, September 25th. JPMorgan Chase & Co. raised shares of Charles River Laboratories International from a “neutral” rating to an “overweight” rating and upped their price objective for the company from $180.00 to $310.00 in a research note on Thursday, August 6th. Morgan Stanley increased their price objective on shares of Charles River Laboratories International from $300.00 to $340.00 and gave the stock an “overweight” rating in a report on Monday, October 12th. Finally, Deutsche Bank Aktiengesellschaft raised their target price on shares of Charles River Laboratories International from $300.00 to $320.00 and gave the stock a “buy” rating in a research report on Friday, September 25th.

Insider Activity

In other Charles River Laboratories International news, EVP Victoria Creamer sold 4,179 shares of Charles River Laboratories International stock in a transaction on Thursday, August 6th. The shares were sold at an average price of $259.16, for a total value of $1,083,029.64. Following the transaction, the executive vice president owned 30,051 shares in the company, valued at $7,788,017.16. This trade represents a 12.21% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, Director James Foster sold 33,561 shares of the business’s stock in a transaction on Tuesday, August 25th. The shares were sold at an average price of $300.00, for a total transaction of $10,068,300.00. Following the sale, the director directly owned 31,596 shares of the company’s stock, valued at $9,478,800. This represents a 51.51% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 118,169 shares of company stock valued at $35,191,216 in the last ninety days. 1.30% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Several large investors have recently made changes to their positions in CRL. Virtue Capital Management LLC purchased a new stake in shares of Charles River Laboratories International during the 3rd quarter worth about $278,000. Sumitomo Mitsui Trust Group Inc. raised its holdings in Charles River Laboratories International by 6.3% in the third quarter. Sumitomo Mitsui Trust Group Inc. now owns 2,869 shares of the medical research company’s stock valued at $846,000 after buying an additional 170 shares during the period. Mirae Asset Global Investments Co. Ltd. purchased a new position in Charles River Laboratories International in the third quarter valued at approximately $7,399,000. Vise Technologies Inc. raised its holdings in Charles River Laboratories International by 58.9% in the third quarter. Vise Technologies Inc. now owns 3,831 shares of the medical research company’s stock valued at $1,130,000 after buying an additional 1,420 shares during the period. Finally, Avestar Capital LLC acquired a new position in Charles River Laboratories International during the third quarter valued at approximately $361,000. 98.91% of the stock is owned by hedge funds and other institutional investors.

Charles River Laboratories International Trading Up 0.5%

Shares of CRL opened at $376.03 on Friday. The stock has a fifty day moving average of $300.76 and a two-hundred day moving average of $221.64. The company has a debt-to-equity ratio of 0.92, a quick ratio of 1.04 and a current ratio of 1.35. The company has a market capitalization of $17.95 billion, a PE ratio of -77.53, a price-to-earnings-growth ratio of 3.50 and a beta of 1.40. Charles River Laboratories International has a fifty-two week low of $146.20 and a fifty-two week high of $379.63.

Charles River Laboratories International (NYSE:CRL) last issued its quarterly earnings results on Wednesday, August 5th. The medical research company reported $3.02 earnings per share for the quarter, topping analysts’ consensus estimates of $2.77 by $0.25. Charles River Laboratories International had a positive return on equity of 15.75% and a negative net margin of 5.96%. The company had revenue of $1 billion for the quarter, compared to analyst estimates of $980.53 million. During the same quarter in the prior year, the company posted $3.12 EPS. The business’s revenue for the quarter was down 2.7% compared to the same quarter last year. Charles River Laboratories International has set its FY 2026 guidance at 11.150-11.450 EPS. As a group, analysts forecast that Charles River Laboratories International will post 11.38 EPS for the current year.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc is a contract research and laboratory services company that supports pharmaceutical, biotechnology, medical device and academic research organizations. The company provides products and services used throughout the drug-development process, from early discovery and research through preclinical testing and manufacturing support.

Its offerings include research models, laboratory animal management, discovery and safety assessment services, toxicology testing, bioanalysis, and support for biologic, cell and gene therapy programs.